Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis

Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2011-06, Vol.9 (6), p.483-489.e3
Hauptverfasser: Ardizzone, Sandro, Cassinotti, Andrea, Duca, Piergiorgio, Mazzali, Cristina, Penati, Chiara, Manes, Gianpiero, Marmo, Riccardo, Massari, Alessandro, Molteni, Paola, Maconi, Giovanni, Porro, Gabriele Bianchi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 489.e3
container_issue 6
container_start_page 483
container_title Clinical gastroenterology and hepatology
container_volume 9
creator Ardizzone, Sandro
Cassinotti, Andrea
Duca, Piergiorgio
Mazzali, Cristina
Penati, Chiara
Manes, Gianpiero
Marmo, Riccardo
Massari, Alessandro
Molteni, Paola
Maconi, Giovanni
Porro, Gabriele Bianchi
description Background & Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.
doi_str_mv 10.1016/j.cgh.2010.12.028
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_869404520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1542356510013431</els_id><sourcerecordid>869404520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEoqXwA7gg3zjt1nbiJBYSUrVQWmmhSNCz5UwmWy_euPU4rfbf42gXDhw4eax570nzvaJ4K_hScFGfb5ewuVtKPv_lksv2WXEqVCUXTSOq58e5VLU6KV4RbTmXutLNy-JECqFVo-vT4unrBIGsZ1dovRs37HvE3kEitrYJ2c2UIOyQ2MWQMLJ0h-zSRUpsFaZIyMKQp5hczsj74HpiQ4jsGz75Pfvk7GYMhD279YDRJveIWe5dcvS6eDFYT_jm-J4Vt5eff66uFuubL9eri_UClKjTohe6FSDztTDYWleNGrAdlKrKrleV7mooh6bWQuq-UYAdlBp4yxFkWzVdo8uz4v0h9z6GhwkpmZ0jQO_tiGEi0-ZQXinJs1IclBADUcTB3Ee3s3FvBDczbrM1GbeZcRshTcadPe-O6VO3w_6v4w_fLPhwEGC-8dFhNAQOR8iMI0IyfXD_jf_4jxtyRw6s_4V7pG3uYMzwjDCUDebH3Pdct-BclFUpyt-rxqWz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>869404520</pqid></control><display><type>article</type><title>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ardizzone, Sandro ; Cassinotti, Andrea ; Duca, Piergiorgio ; Mazzali, Cristina ; Penati, Chiara ; Manes, Gianpiero ; Marmo, Riccardo ; Massari, Alessandro ; Molteni, Paola ; Maconi, Giovanni ; Porro, Gabriele Bianchi</creator><creatorcontrib>Ardizzone, Sandro ; Cassinotti, Andrea ; Duca, Piergiorgio ; Mazzali, Cristina ; Penati, Chiara ; Manes, Gianpiero ; Marmo, Riccardo ; Massari, Alessandro ; Molteni, Paola ; Maconi, Giovanni ; Porro, Gabriele Bianchi</creatorcontrib><description>Background &amp; Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2010.12.028</identifier><identifier>PMID: 21195796</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adrenal Cortex Hormones - administration &amp; dosage ; Adult ; Anti-Inflammatory Agents - administration &amp; dosage ; Clinical Course ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - pathology ; Drug Monitoring - methods ; Endoscopy ; Female ; Follow-Up Studies ; Gastroenterology and Hepatology ; Humans ; Inflammatory Bowel Diseases ; Intestinal Mucosa - pathology ; Male ; Middle Aged ; Mucosal Healing ; Prognosis ; Treatment Outcome</subject><ispartof>Clinical gastroenterology and hepatology, 2011-06, Vol.9 (6), p.483-489.e3</ispartof><rights>AGA Institute</rights><rights>2011 AGA Institute</rights><rights>Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</citedby><cites>FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2010.12.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21195796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ardizzone, Sandro</creatorcontrib><creatorcontrib>Cassinotti, Andrea</creatorcontrib><creatorcontrib>Duca, Piergiorgio</creatorcontrib><creatorcontrib>Mazzali, Cristina</creatorcontrib><creatorcontrib>Penati, Chiara</creatorcontrib><creatorcontrib>Manes, Gianpiero</creatorcontrib><creatorcontrib>Marmo, Riccardo</creatorcontrib><creatorcontrib>Massari, Alessandro</creatorcontrib><creatorcontrib>Molteni, Paola</creatorcontrib><creatorcontrib>Maconi, Giovanni</creatorcontrib><creatorcontrib>Porro, Gabriele Bianchi</creatorcontrib><title>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Background &amp; Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.</description><subject>Adrenal Cortex Hormones - administration &amp; dosage</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration &amp; dosage</subject><subject>Clinical Course</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Drug Monitoring - methods</subject><subject>Endoscopy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology and Hepatology</subject><subject>Humans</subject><subject>Inflammatory Bowel Diseases</subject><subject>Intestinal Mucosa - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mucosal Healing</subject><subject>Prognosis</subject><subject>Treatment Outcome</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhSMEoqXwA7gg3zjt1nbiJBYSUrVQWmmhSNCz5UwmWy_euPU4rfbf42gXDhw4eax570nzvaJ4K_hScFGfb5ewuVtKPv_lksv2WXEqVCUXTSOq58e5VLU6KV4RbTmXutLNy-JECqFVo-vT4unrBIGsZ1dovRs37HvE3kEitrYJ2c2UIOyQ2MWQMLJ0h-zSRUpsFaZIyMKQp5hczsj74HpiQ4jsGz75Pfvk7GYMhD279YDRJveIWe5dcvS6eDFYT_jm-J4Vt5eff66uFuubL9eri_UClKjTohe6FSDztTDYWleNGrAdlKrKrleV7mooh6bWQuq-UYAdlBp4yxFkWzVdo8uz4v0h9z6GhwkpmZ0jQO_tiGEi0-ZQXinJs1IclBADUcTB3Ee3s3FvBDczbrM1GbeZcRshTcadPe-O6VO3w_6v4w_fLPhwEGC-8dFhNAQOR8iMI0IyfXD_jf_4jxtyRw6s_4V7pG3uYMzwjDCUDebH3Pdct-BclFUpyt-rxqWz</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Ardizzone, Sandro</creator><creator>Cassinotti, Andrea</creator><creator>Duca, Piergiorgio</creator><creator>Mazzali, Cristina</creator><creator>Penati, Chiara</creator><creator>Manes, Gianpiero</creator><creator>Marmo, Riccardo</creator><creator>Massari, Alessandro</creator><creator>Molteni, Paola</creator><creator>Maconi, Giovanni</creator><creator>Porro, Gabriele Bianchi</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110601</creationdate><title>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</title><author>Ardizzone, Sandro ; Cassinotti, Andrea ; Duca, Piergiorgio ; Mazzali, Cristina ; Penati, Chiara ; Manes, Gianpiero ; Marmo, Riccardo ; Massari, Alessandro ; Molteni, Paola ; Maconi, Giovanni ; Porro, Gabriele Bianchi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-d1981c2101cfa69475fe8f5543bd549b6c3f769129d75cebc39c080ec2847b793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adrenal Cortex Hormones - administration &amp; dosage</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration &amp; dosage</topic><topic>Clinical Course</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Drug Monitoring - methods</topic><topic>Endoscopy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology and Hepatology</topic><topic>Humans</topic><topic>Inflammatory Bowel Diseases</topic><topic>Intestinal Mucosa - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mucosal Healing</topic><topic>Prognosis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ardizzone, Sandro</creatorcontrib><creatorcontrib>Cassinotti, Andrea</creatorcontrib><creatorcontrib>Duca, Piergiorgio</creatorcontrib><creatorcontrib>Mazzali, Cristina</creatorcontrib><creatorcontrib>Penati, Chiara</creatorcontrib><creatorcontrib>Manes, Gianpiero</creatorcontrib><creatorcontrib>Marmo, Riccardo</creatorcontrib><creatorcontrib>Massari, Alessandro</creatorcontrib><creatorcontrib>Molteni, Paola</creatorcontrib><creatorcontrib>Maconi, Giovanni</creatorcontrib><creatorcontrib>Porro, Gabriele Bianchi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ardizzone, Sandro</au><au>Cassinotti, Andrea</au><au>Duca, Piergiorgio</au><au>Mazzali, Cristina</au><au>Penati, Chiara</au><au>Manes, Gianpiero</au><au>Marmo, Riccardo</au><au>Massari, Alessandro</au><au>Molteni, Paola</au><au>Maconi, Giovanni</au><au>Porro, Gabriele Bianchi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>9</volume><issue>6</issue><spage>483</spage><epage>489.e3</epage><pages>483-489.e3</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Background &amp; Aims It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. Methods Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel–Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0–1; Baron, 0), partial (group B: PT, 0–1; Baron, 1–3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. Results After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21–6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67–25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24–32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12–6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193–51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556–8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278–55.186; P = .0268). Conclusions No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21195796</pmid><doi>10.1016/j.cgh.2010.12.028</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2011-06, Vol.9 (6), p.483-489.e3
issn 1542-3565
1542-7714
language eng
recordid cdi_proquest_miscellaneous_869404520
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adrenal Cortex Hormones - administration & dosage
Adult
Anti-Inflammatory Agents - administration & dosage
Clinical Course
Colitis, Ulcerative - drug therapy
Colitis, Ulcerative - pathology
Drug Monitoring - methods
Endoscopy
Female
Follow-Up Studies
Gastroenterology and Hepatology
Humans
Inflammatory Bowel Diseases
Intestinal Mucosa - pathology
Male
Middle Aged
Mucosal Healing
Prognosis
Treatment Outcome
title Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T19%3A56%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mucosal%20Healing%20Predicts%20Late%20Outcomes%20After%20the%20First%20Course%20of%20Corticosteroids%20for%20Newly%20Diagnosed%20Ulcerative%20Colitis&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Ardizzone,%20Sandro&rft.date=2011-06-01&rft.volume=9&rft.issue=6&rft.spage=483&rft.epage=489.e3&rft.pages=483-489.e3&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2010.12.028&rft_dat=%3Cproquest_cross%3E869404520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=869404520&rft_id=info:pmid/21195796&rft_els_id=1_s2_0_S1542356510013431&rfr_iscdi=true